Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niklas Reich

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Frontiers in Neuroscience|September 19, 2022
The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth reviewNiklas Reich, Christian Hölscher
Frontiers in Neuroscience|December 31, 2020
Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's DiseaseNiklas Reich, Christian Hölscher
Neuroscience and Biobehavioral Reviews|November 11, 2022
Beyond appetite: Acylated ghrelin as a learning, memory and fear behavior-modulating hormoneNiklas Reich, Christian Hölscher
Frontiers in Neuroendocrinology|February 12, 2024
Cholecystokinin (CCK): a neuromodulator with therapeutic potential in Alzheimer's and Parkinson's diseaseNiklas Reich, Christian Hölscher
Neuroscience and Biobehavioral Reviews|February 8, 2024
Using caffeine as a chemical means to induce flow statesNiklas Reich, Michael Mannino, Steven Kotler
Journal of Cellular and Molecular Medicine|June 10, 2024
Liposome nanoparticle conjugation and cell penetrating peptide sequences (CPPs) enhance the cellular delivery of the tau aggregation inhibitor RI-AG03Niklas Reich, Edward Parkin, Neil Dawson
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Frontiers in Neuroscience|September 19, 2022
The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth reviewNiklas Reich, Christian Hölscher
Frontiers in Neuroscience|December 31, 2020
Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's DiseaseNiklas Reich, Christian Hölscher
Neuroscience and Biobehavioral Reviews|November 11, 2022
Beyond appetite: Acylated ghrelin as a learning, memory and fear behavior-modulating hormoneNiklas Reich, Christian Hölscher
Frontiers in Neuroendocrinology|February 12, 2024
Cholecystokinin (CCK): a neuromodulator with therapeutic potential in Alzheimer's and Parkinson's diseaseNiklas Reich, Christian Hölscher
Neuroscience and Biobehavioral Reviews|February 8, 2024
Using caffeine as a chemical means to induce flow statesNiklas Reich, Michael Mannino, Steven Kotler
Journal of Cellular and Molecular Medicine|June 10, 2024
Liposome nanoparticle conjugation and cell penetrating peptide sequences (CPPs) enhance the cellular delivery of the tau aggregation inhibitor RI-AG03Niklas Reich, Edward Parkin, Neil Dawson
Pageof 1